DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on April 19, 2006; DOI: 10.1124/dmd.105.009126


0090-9556/06/3407-1145-1151$20.00
DMD 34:1145-1151, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum
Right arrow An erratum has been published
Right arrow All Versions of this Article:
dmd.105.009126v1
34/7/1145    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kang, H.-J.
Right arrow Articles by Shin, J.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, H.-J.
Right arrow Articles by Shin, J.-G.

NEUROTOXIC PYRIDINIUM METABOLITES OF HALOPERIDOL ARE SUBSTRATES OF HUMAN ORGANIC CATION TRANSPORTERS

Ho-Jin Kang, Sang-Seop Lee, Chung-Hee Lee, Ju-Cheol Shim, Ho Jung Shin, Kwang-Hyeon Liu, Mi-Ae Yoo, and Jae-Gook Shin

Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan, Korea (H.-J.K., S.-S.L., C.-H.L., J.-C.S., H.J.S., K.-H.L., J.-G.S.); and Department of Molecular Biology, College of Natural Sciences, Busan National University, Busan, Korea (H.-J.K., M.-A.Y.)

Two neurotoxic pyridinium metabolites of haloperidol, 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxybutyl]pyridinium ion (HPP+) and 4-(4-(chlorophenyl)-1–4-(fluorophenyl)-4-hydroxybutyl-pyridinium (RHPP+), are formed in the liver and found in the brain. To understand how these neurotoxic pyridinium metabolites are distributed in the brain, HPP+ and RHPP+ were evaluated as substrates for human organic cation transporters (hOCTs). Both HPP+ and RHPP+ were accumulated in Caco-2 cells, and these accumulations were significantly inhibited by pretreatment with the hOCT inhibitors verapamil, cimetidine, phenoxybenzamine, and corticosterone. The contribution of each hOCT was evaluated based on measurements of the intracellular concentrations of haloperidol metabolites in Madin Darby canine kidney (MDCK) cells transfected with hOCT1, hOCT2, or hOCT3. HPP+ accumulated in hOCT-overexpressing MDCK cells in a concentration-dependent manner, with estimated Km values of 0.99, 2.79, and 2.23 µM and Vmax values of 282.1, 256.1, and 400.2 pmol/min/µg protein for hOCT1, hOCT2, and hOCT3, respectively. RHPP+ accumulated in hOCT1- and hOCT3-overexpressing MDCK cells, with estimated Km values of 5.15 and 8.21 µM and Vmax values of 1230.9 and 1348.6 pmol/min/µg protein for hOCT1 and hOCT3, respectively. On the other hand, RHPP+ did not accumulate in the hOCT2-expressing MDCK cells. These results suggest that HPP+ and RHPP+ are substrates for hOCTs, with the exception of RHPP+ for hOCT2. Thus, hOCTs seem to contribute to the disposition of these toxic metabolites in human subjects, although further in vivo studies are required to elucidate the involvement of hOCTs in the disposition of haloperidol pyridinium metabolites.


Address correspondence to: Dr. Jae-Gook Shin, Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Department of Clinical Pharmacology, Busan Paik Hospital, 633-165 Gaegum-Dong, Jin-Gu, Busan 614-735, Korea. E-mail: phshinjg{at}inge.ac.kr




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
H.-J. Kang, I.-S. Song, H. J. Shin, W.-Y. Kim, C.-H. Lee, J.-C. Shim, H.-H. Zhou, S. S. Lee, and J.-G. Shin
Identification and Functional Characterization of Genetic Variants of Human Organic Cation Transporters in a Korean Population
Drug Metab. Dispos., April 1, 2007; 35(4): 667 - 675.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.